secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACTUATE THERAPEUTICS, INC. (ACTU)
CIK:        0001652935
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001683168-25-001945
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actuate Therapeutics enters $50M equity line with B. Riley, can sell shares at 3% VWAP discount
--------------------------------------------------------------------------------

- Company may sell up to $50M of common stock to B. Riley Principal Capital II over 36 months at a 3% discount to VWAP.
- Sales are at Actuate's sole discretion; no obligation to sell any shares under the agreement.
- Beneficial ownership by B. Riley capped at 4.99%; exchange cap of 19.99% of shares outstanding unless higher threshold price met.
- Actuate paid a cash commitment fee of up to $500,000 (1% of facility) and will reimburse legal fees.
- Proceeds intended for working capital and general corporate purposes; company retains right to terminate at any time with 10 trading days' notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652935/000168316825001945/0001683168-25-001945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652935/000168316825001945/actuate_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-001945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer